

# Judith S Currier

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9230459/publications.pdf>

Version: 2024-02-01

76  
papers

2,053  
citations

279798

23  
h-index

276875

41  
g-index

82  
all docs

82  
docs citations

82  
times ranked

3574  
citing authors

#	ARTICLE	IF	CITATIONS
1	Transfusing Convalescent Plasma as Post-Exposure Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Double-Blinded, Phase 2 Randomized, Controlled Trial. <i>Clinical Infectious Diseases</i> , 2023, 76, e477-e486.	5.8	29
2	Distinct Lipidomic Signatures in People Living With HIV: Combined Analysis of ACTG 5260s and MACS/WIHS. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 119-135.	3.6	1
3	COVID-19 Vaccination Rates in a Global HIV Cohort. <i>Journal of Infectious Diseases</i> , 2022, 225, 603-607.	4.0	8
4	Factors Associated With Systemic Immune Activation Indices in a Global Primary Cardiovascular Disease Prevention Cohort of People With Human Immunodeficiency Virus on Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2022, 75, 1324-1333.	5.8	8
5	Proteomic Signature of Subclinical Coronary Artery Disease in People With HIV: Analysis of the REPRIEVE Mechanistic Substudy. <i>Journal of Infectious Diseases</i> , 2022, 226, 1809-1822.	4.0	11
6	Non-communicable Diseases in Pregnant and Postpartum Women Living with HIV: Implications for Health Throughout the Life Course. <i>Current HIV/AIDS Reports</i> , 2021, 18, 73-86.	3.1	13
7	HIV and women in the USA: what we know and where to go from here. <i>Lancet, The</i> , 2021, 397, 1107-1115.	13.7	35
8	Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial. <i>Lancet, The</i> , 2021, 397, 1276-1292.	13.7	82
9	Brief Report: Impact of ART on Maternal Health After Cessation of Breastfeeding. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 86, 450-454.	2.1	1
10	SARS-CoV-2 Infection after Vaccination in Health Care Workers in California. <i>New England Journal of Medicine</i> , 2021, 384, 1774-1775.	27.0	231
11	Assessment of Coronary Artery Disease With Computed Tomography Angiography and Inflammatory and Immune Activation Biomarkers Among Adults With HIV Eligible for Primary Cardiovascular Prevention. <i>JAMA Network Open</i> , 2021, 4, e2114923.	5.9	38
12	Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial. <i>Clinical Infectious Diseases</i> , 2021, 73, 2009-2022.	5.8	19
13	Advanced Glycation End Products Associated With Cardiometabolic Biomarkers In Treated HIV Infection. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab423.	0.9	1
14	Poorer Muscle Quality and Quantity With ART Initiation Is Associated With Greater Inflammation and Immune Activation. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 88, 399-405.	2.1	3
15	Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV): Designing Master Protocols for Evaluation of Candidate COVID-19 Therapeutics. <i>Annals of Internal Medicine</i> , 2021, 174, 1293-1300.	3.9	26
16	Machine Learning Algorithms Using Routinely Collected Data Do Not Adequately Predict Viremia to Inform Targeted Services in Postpartum Women Living With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 88, 439-447.	2.1	4
17	Maternal HBV Viremia and Association With Adverse Infant Outcomes in Women Living With HIV and HBV. <i>Pediatric Infectious Disease Journal</i> , 2021, 40, e56-e61.	2.0	5
18	Lower SARS-CoV-2 viral shedding following COVID-19 vaccination among healthcare workers in Los Angeles, California. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab526.	0.9	5

#	ARTICLE	IF	CITATIONS
19	Assessment of Obesity and Cardiometabolic Status by Integrase Inhibitor Use in REPRIEVE: A Propensity-Weighted Analysis of a Multinational Primary Cardiovascular Prevention Cohort of People With Human Immunodeficiency Virus. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab537.	0.9	19
20	Immune Biomarkers in the Prediction of Future Myocardial Infarctions in People With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2020, 70, 1764-1767.	5.8	6
21	Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial. <i>Journal of Infectious Diseases</i> , 2020, 222, S8-S19.	4.0	8
22	Correlates and Timing of Reproductive Aging Transitions in a Global Cohort of Midlife Women With Human Immunodeficiency Virus: Insights From the REPRIEVE Trial. <i>Journal of Infectious Diseases</i> , 2020, 222, S20-S30.	4.0	16
23	Predictors of Viremia in Postpartum Women on Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 83, 72-80.	2.1	5
24	The impact of short term Antiretroviral Therapy (ART) interruptions on longer term maternal health outcomes—A randomized clinical trial. <i>PLoS ONE</i> , 2020, 15, e0228003.	2.5	3
25	Excess Patient Visits for Cough and Pulmonary Disease at a Large US Health System in the Months Prior to the COVID-19 Pandemic: Time-Series Analysis. <i>Journal of Medical Internet Research</i> , 2020, 22, e21562.	4.3	14
26	Outcomes of a Career Development Program for Underrepresented Minority Investigators in the AIDS Clinical Trials Group. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz069.	0.9	4
27	Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE). <i>American Heart Journal</i> , 2019, 212, 23-35.	2.7	99
28	Racial Disparities in Virologic Failure and Tolerability During Firstline HIV Antiretroviral Therapy. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz022.	0.9	4
29	Changes in the Fungal Marker $\beta$ -D-Glucan After Antiretroviral Therapy and Association With Adiposity. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz434.	0.9	15
30	Tenofovir concentrations in hair strongly predict virologic suppression in breastfeeding women. <i>Aids</i> , 2019, 33, 1657-1662.	2.2	11
31	Antiretroviral Concentrations in Hair Strongly Predict Virologic Response in a Large Human Immunodeficiency Virus Treatment-naïve Clinical Trial. <i>Clinical Infectious Diseases</i> , 2019, 68, 1044-1047.	5.8	22
32	Safety and Impact of Low-dose Methotrexate on Endothelial Function and Inflammation in Individuals With Treated Human Immunodeficiency Virus: AIDS Clinical Trials Group Study A5314. <i>Clinical Infectious Diseases</i> , 2019, 68, 1877-1886.	5.8	42
33	What Is the Best Model for HIV Primary Care? Assessing the Influence of Provider Type on Outcomes of Chronic Comorbidities in HIV Infection. <i>Journal of Infectious Diseases</i> , 2018, 218, 337-339.	4.0	12
34	Telmisartan Therapy Does Not Improve Lymph Node or Adipose Tissue Fibrosis More Than Continued Antiretroviral Therapy Alone. <i>Journal of Infectious Diseases</i> , 2018, 217, 1770-1781.	4.0	23
35	Low Levels of Endothelial Progenitor Cells and Their Association with Systemic Inflammation and Monocyte Activation in Older HIV-Infected Men. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 39-45.	1.1	9
36	Development and validation of an assay to analyze atazanavir in human hair via liquid chromatography/tandem mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2018, 32, 431-441.	1.5	11

#	ARTICLE	IF	CITATIONS
37	Maternal health outcomes among HIV-infected breastfeeding women with high CD4 counts: results of a treatment strategy trial. <i>HIV Clinical Trials</i> , 2018, 19, 209-224.	2.0	10
38	Changes in Waist Circumference in HIV-Infected Individuals Initiating a Raltegravir or Protease Inhibitor Regimen: Effects of Sex and Race. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy201.	0.9	55
39	Pregnancy outcomes among HIV-infected women who conceived on antiretroviral therapy. <i>PLoS ONE</i> , 2018, 13, e0199555.	2.5	46
40	Follow YOUR Heart: development of an evidence-based campaign empowering older women with HIV to participate in a large-scale cardiovascular disease prevention trial. <i>HIV Clinical Trials</i> , 2017, 18, 83-91.	2.0	14
41	Subclinical myocardial disease by cardiac magnetic resonance imaging and spectroscopy in healthy HIV/Hepatitis C virus-coinfected persons. <i>Journal of International Medical Research</i> , 2017, 45, 1693-1707.	1.0	10
42	Transgender Women Living with HIV Frequently Take Antiretroviral Therapy and/or Feminizing Hormone Therapy Differently Than Prescribed Due to Drug-Drug Interaction Concerns. <i>LGBT Health</i> , 2017, 4, 371-375.	3.4	47
43	Refining Current Scientific Priorities and Identifying New Scientific Gaps in HIV-Related Heart, Lung, Blood, and Sleep Research. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 889-897.	1.1	6
44	Factors associated with retention in Option B+ in Malawi: a case control study. <i>Journal of the International AIDS Society</i> , 2017, 20, 21464.	3.0	33
45	Randomized trial of stopping or continuing ART among postpartum women with pre-ART CD4 $\geq$ 400 cells/mm <sup>3</sup> . <i>PLoS ONE</i> , 2017, 12, e0176009.	2.5	23
46	Changes in Abdominal Fat following Antiretroviral Therapy Initiation in HIV-Infected Individuals Correlate with Waist Circumference and Self-Reported Changes. <i>Antiviral Therapy</i> , 2017, 22, 577-586.	1.0	13
47	A Cure for HIV Infection: "Not in My Lifetime" or "Just Around the Corner". <i>Pathogens and Immunity</i> , 2016, 1, 154.	3.1	35
48	Changes in Markers of T-Cell Senescence and Exhaustion With Atazanavir-, Raltegravir-, and Darunavir-Based Initial Antiviral Therapy: ACTG 5260s. <i>Journal of Infectious Diseases</i> , 2016, 214, 748-752.	4.0	9
49	Soluble Levels of Receptor for Advanced Glycation Endproducts (RAGE) and Progression of Atherosclerosis in Individuals Infected with Human Immunodeficiency Virus: ACTG NWCS 332. <i>Inflammation</i> , 2016, 39, 1354-1362.	3.8	5
50	Telmisartan increases vascular reparative capacity in older HIV-infected adults: a pilot study. <i>HIV Clinical Trials</i> , 2016, 17, 225-232.	2.0	5
51	Changes in Insulin Resistance After Initiation of Raltegravir or Protease Inhibitors With Tenofovir-Emtricitabine: AIDS Clinical Trials Group A5260s. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw174.	0.9	38
52	Making waves: safety and efficacy of ART in women. <i>Lancet HIV</i> , 2016, 3, e398-e399.	4.7	2
53	Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention. <i>New England Journal of Medicine</i> , 2016, 375, 1726-1737.	27.0	268
54	Traditional and HIV-specific risk factors for cardiovascular morbidity and mortality among HIV-infected adults in Brazil: a retrospective cohort study. <i>BMC Infectious Diseases</i> , 2016, 16, 376.	2.9	19

#	ARTICLE	IF	CITATIONS
55	Supporting Treatment Adherence Readiness through Training (START) for patients with HIV on antiretroviral therapy: study protocol for a randomized controlled trial. <i>Trials</i> , 2016, 17, 162.	1.6	12
56	HIV Infection and Carotid Artery Intima-media Thickness: Pooled Analyses Across 5 Cohorts of the NHLBI HIV-CVD Collaborative. <i>Clinical Infectious Diseases</i> , 2016, 63, 249-256.	5.8	51
57	Vitamin D Levels and Markers of Inflammation and Metabolism in HIV-Infected Individuals on Suppressive Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 247-254.	1.1	9
58	Switch to Raltegravir From Protease Inhibitor or Nonnucleoside Reverse-Transcriptase Inhibitor Does not Reduce Visceral Fat In Human Immunodeficiency Virus-Infected Women With Central Adiposity. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv059.	0.9	6
59	Benefits of PrEP as an Adjunctive Method of HIV Prevention During Attempted Conception Between HIV-uninfected Women and HIV-infected Male Partners. <i>Journal of Infectious Diseases</i> , 2015, 212, 1534-1543.	4.0	22
60	Stimulating High Impact HIV-Related Cardiovascular Research. <i>Journal of the American College of Cardiology</i> , 2015, 65, 738-744.	2.8	17
61	Short Communication: Coronary Heart Disease Risk by Framingham Risk Score in Hepatitis C and HIV/Hepatitis C-Coinfected Persons. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 718-722.	1.1	25
62	Concurrent Anemia and Elevated C-Reactive Protein Predicts HIV Clinical Treatment Failure, Including Tuberculosis, After Antiretroviral Therapy Initiation. <i>Clinical Infectious Diseases</i> , 2015, 61, 102-110.	5.8	21
63	Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir. <i>Journal of Infectious Diseases</i> , 2015, 212, 1241-1249.	4.0	100
64	Immune Activation Markers in Peripartum Women in Botswana: Association with Feeding Strategy and Maternal Morbidity. <i>PLoS ONE</i> , 2014, 9, e89928.	2.5	5
65	A High Throughput Biochemical Fluorometric Method for Measuring Lipid Peroxidation in HDL. <i>PLoS ONE</i> , 2014, 9, e111716.	2.5	24
66	Who Provides Primary Care? An Assessment of HIV Patient and Provider Practices and Preferences. <i>Journal of AIDS &amp; Clinical Research</i> , 2014, 05, .	0.5	23
67	Dyslipidemia and Cardiovascular Risk in Human Immunodeficiency Virus Infection. <i>Endocrinology and Metabolism Clinics of North America</i> , 2014, 43, 665-684.	3.2	35
68	Arterial Disease in Patients With Human Immunodeficiency Virus Infection. <i>JACC: Cardiovascular Imaging</i> , 2014, 7, 515-525.	5.3	44
69	Hdl Redox Activity is Increased in HIV-Infected Men in Association with Macrophage Activation and Non-Calcified Coronary Atherosclerotic Plaque. <i>Antiviral Therapy</i> , 2014, 19, 805-811.	1.0	16
70	Role of RANKL-RANK/osteoprotegerin pathway in cardiovascular and bone disease associated with HIV infection. <i>AIDS Reviews</i> , 2014, 16, 123-33.	1.0	8
71	Maternal Outcomes after Haart for the Prevention of Mother-To-Child Transmission in HIV-Infected Women in Brazil. <i>Antiviral Therapy</i> , 2011, 16, 349-356.	1.0	8
72	A biochemical fluorometric method for assessing the oxidative properties of HDL. <i>Journal of Lipid Research</i> , 2011, 52, 2341-2351.	4.2	70

#	ARTICLE	IF	CITATIONS
73	Effects of Darunavir/Ritonavir-Based Therapy on Metabolic and Anthropometric Parameters in Women and Men Over 48 Weeks. <i>AIDS Patient Care and STDs</i> , 2011, 25, 333-340.	2.5	13
74	Regional Adipose Tissue and Lipid and Lipoprotein Levels in HIV-Infected Women. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2008, 48, 35-43.	2.1	43
75	Management of metabolic complications of therapy. <i>Aids</i> , 2002, 16, S171-S176.	2.2	3
76	Identifying and managing morphologic complications of HIV and HAART. <i>Aids Reader</i> , 2002, 12, 114-9, 124-5.	0.3	8